Scales as outcome measures for Alzheimer's disease
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The assessment of patient outcomes in clinical trials of new therapeutics for Alzheimer's disease (AD) continues to evolve. In addition to assessing drugs for symptomatic relief, an increasing number of trials are focusing on potential disease‐modifying agents. Moreover, participants with AD are being studied earlier in their course of disease. As a result, the limitations of current outcome measures have become more apparent, as has the need for better instruments. In recognition of the need to review and possibly revise current assessment measures, the Alzheimer's Association, in cooperation with industry leaders and academic investigators, convened a Research Roundtable meeting devoted to scales as outcome measures for AD clinical trials. The meeting included a discussion of methodological issues in the use of scales in AD clinical trials, including cross‐cultural issues. Specific topics related to the use of cognitive, functional, global, and neuropsychiatric scales were also presented. Speakers also addressed academic and industry initiatives for pooling data from untreated and placebo‐treated patients in clinical trials. A number of regulatory topics were also discussed with agency representatives. Panel discussions highlighted areas of controversy, in an effort to gain consensus on various topics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Randolph, C., Tierney, M. C., Mohr, E., & Chase, T. N. (1998) · Journal of Clinical and Experimental Neuropsychology · doi:10.1076/jcen.20.3.310.823 · Cited by 2,519 · cited 1×
“The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) is another cognitive test that is relatively simple to administer, has minimal practice effects, and seems sensitive in MCI and mild-AD participants [44].”
MethodA Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844 · cited 7×
“Analysis of covariance is frequently used by imputing missing data according to the last-observation-carried-forward approach, whereas GEE and random-effects models assume that progression can reasonably be modeled based on linear changes over time, which may or may not be true.”
MethodInfluentialHambleton, R. K., & Swaminathan, H. (1985) · doi:10.1007/978-94-017-1988-9 · Cited by 1,777
Andrich, D. (1988) · doi:10.4135/9781412985598 · Cited by 1,345
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2005.06.003 · Cited by 1,233
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206
Self-citationRobbins, T. W., James, M., Owen, A. M., Sahakian, B. J., McInnes, L., & Rabbitt, P. (1994) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000106735 · Cited by 1,078
Grundman, M. (2004) · Archives of Neurology · doi:10.1001/archneur.61.1.59 · Cited by 972 · cited 2×
“In the ADCS MCI Trial, for example, placebo groups did not change much over 36 months according to both MMSE and ADAS-Cog/13 item version [36].”
Method
Cited by
Babulal, G. M., Quiroz, Y. T., Albensi, B. C., Arenaza‐Urquijo, E., Astell, A. J., Babiloni, C., Bahar‐Fuchs, A., Bell, J., Bowman, G. L., Brickman, A. M., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.09.009 · Cited by 528
“Reading measures created in one language do not necessarily translate well into other languages due to a variety of factors [39].”
BackgroundSelf-citationNeuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future
Geda, Y. E., Schneider, L. S., Gitlin, L. N., Miller, D. S., Smith, G. S., Bell, J., Evans, J., Lee, M., Porsteinsson, A., Lanctôt, K. L., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.12.001 · Cited by 378
“Keywords: Neuropsychiatric symptoms; Behavioral and psychological symptoms of dementia; Agitation/aggression; Sleep disorders; Depression; Apathy; Psychosis; Delusions; Hallucinations; Dementia; Alzheimer’s disease; Mild cognitive impairment; Mild behavioral impairment”
BackgroundSelf-citationShah, R. C., Kamphuis, P. J., Leurgans, S., Swinkels, S. H., Sadowsky, C. H., Bongers, A., Rappaport, S. A., Quinn, J. F., Wieggers, R. L., Scheltens, P., et al. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt224 · Cited by 112
Assessing atrophy measurement techniques in dementia: results from the MIRIAD atrophy challenge
Cash, D. M., Frost, C., Iheme, L. O., Ünay, D., Kandemir, M., Fripp, J., Salvado, O., Bourgeat, P., Reuter, M., Fischl, B., et al. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.07.087 · Cited by 72
Brunelle-Hamann, L., Thivierge, S., & Simard, M. (2015) · Neuropsychological Rehabilitation · doi:10.1080/09602011.2014.964731 · Cited by 29
“The NPI does not account for rater judgement (Black et al., 2009).”
Background
Metadata
- Authors
- Black, R., Greenberg, B., Ryan, J. M., Posner, H., Seeburger, J., Amatniek, J., Resnick, M., Mohs, R., Miller, D. S., Saumier, D., Carrillo, M. C., & Stern, Y.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2009-07
- Volume
- 5
- Issue
- 4
- Pages
- 324-339
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2030003860
- Cited by
- 50
- References
- 19
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Scales as outcome measures for Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.jalz.2009.05.667
- The paper
- Black, R., Greenberg, B., Ryan, J. M., Posner, H., Seeburger, J., Amatniek, J., Resnick, M., Mohs, R., Miller, D. S., Saumier, D., Carrillo, M. C., & Stern, Y. (2009). Scales as outcome measures for Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2009.05.667
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.